Promising results to date from the Fonds d’accélération des collaborations en santé (FACS) launched by the Government of Quebec in 2017
- Extending the reach of public research, health care and education infrastructures.
- Increasing the efficiency of the health and social services system.
- Developing new concepts, products, tools, processes, practices, services or collaborative models benefiting the life sciences ecosystem, the health and social services system and the Quebec economy.
- Increasing private investments in Quebec.
- Creating value and prosperity for Quebec.
As part of a 1st call for proposals launched in 2017, the Quebec Government invited industry players to submit ambitious projects that promote public-private partnerships and reinforce multi-institutional collaboration. Ultimately, 40 million $ were awarded to achieve 6 large-scale initiatives which were launched in 2018 and will end in 2022. A second call for proposals with a 35 million $ FACS funding envelope was launched in 2020 and the selected initiatives will be announced shortly.
For the Government of Quebec who chose to back these large-scale initiatives, this represents an investment that has already generated a financial leverage of 3.6x. Since the projects are still underway, the magnitude of their economic impact for the province and the project partners is expected to grow considerably.
In the current context, the resulting financial leverage drives economic recovery by attracting private capital to support the development of marketable innovations. In addition, the funds support the discovery and development of new technologies that will maintain Quebec’s edge in life sciences, create and maintain highly specialized jobs and improve patient care and health.
- Morag Park (McGill University) – Quebec Cancer Consortium for Novel Therapeutics and Biomarkers
- Guy Rouleau (McGill University / The Montreal Neurological Institute-Hospital) – Integrating patient data to develop precision medicine therapies for amyotrophic lateral sclerosis and Parkinson’s disease
- Michel Bergeron (CHU de Québec-Université Laval) – Molecular mini-panels for the rapid detection of highly transmissible pathogens
- Jean-Claude Tardif (Montreal Heart Institute) – International leadership in precision medicine clinical studies
- Jean-Claude Tardif (Montreal Heart Institute) – Curbing Atherosclerosis Through Precision Medicine
- Michel Bouvier (University of Montreal / IRIC) – IRIC, universities and industry collaboration: accelerated discovery of novel therapies with a long-term impact
This public funding has attracted 61 million $ in private matching contributions, which underscores the attractiveness of the initiatives for companies in Quebec and abroad. The projects were initiated in 2018 and will all be completed in 2022.